Overview

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

Status:
Active, not recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The main purpose of study is to compatibility the pharmacokinetic (PK) of Process D relative to Process C.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Nivolumab